This phase II study is assessing the effect of targeted therapy (sotorasib) in adults with some advanced cancers that have KRAS G12C mutations.
This trial is treating patients with advanced solid cancers, except for non-small cell lung cancer and colorectal cancers, with KRAS G12C mutations.
This is a systemic therapy trial.
You may be able to join this trial if:
- You are able to swallow medication by mouth.
- You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
- Your cancer has not spread to other parts of the body.
- Your cancer has spread to other parts of the body.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have been diagnosed with a prior or secondary type of cancer.
- You have had certain treatments, surgical procedures or drugs.
- You have previously been treated (or are currently being treated) on a clinical trial.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
Single arm, open label, signal-seeking phase II study of Sotorasib (AMG-510) in patients with solid tumours harbouring KRAS G12C mutation
Australian Genomic Cancer Medicine Centre (AGCMC)
Other Non-Commercial Sponsor
University of Sydney
This is a substudy of the Cancer Molecular Screening and Therapeutics (MoST) Program (ACTRN12616000908437). Eligible participants will receive 8x oral tablets daily of 120mg Sotorasib, for a total daily dose of 960mg. Tablets will be taken continuously over 28 day cycles until disease progression.
Recruiting Hospitals Read More